



Grape King Bio (1707 TT) Investor Presentation

Mar 2021

Confidential



Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs. losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.





Company Background

Confidentia

Investment Highlights



We are industry leader

- ✓ We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements. We command No. 1 position in probiotics and medicinal mushrooms supplements with 31% and 45% market share, respectively in 2019.
- ✓ We operate the second largest direct-selling company Pro-Partner in Taiwan (2019 market share: 8.3%).




Strong R&D capabilities

- ✓ We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
- ✓ Our expertise in raw materials allow us to develop health supplements serving different benefits. Therefore, many of our products are TFDA approved for different health benefits.
- ✓ We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.



Solid growth with sustainable payout ratio

- ✓ We have delivered a solid earnings during 2008-2020 (CAGR of 19%/average ROE 25%).
- ✓ We have maintained more than 60% dividend payout in the past five years.
- ✓ On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.



Company Overview: Three core business units



1. Grape King Taiwan (Parent Co) Taiwan own brand & global OEM & ODM

Locus of all key ingredient design, formulation, and production for the whole Group.




2. Pro-Partner (60%-own) Taiwan direct selling distribution

A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.




3. Grape King Shanghai (100%-own) China OEM & ODM

Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.



2020 REVENUE




Complete Product Range





Competitive Strengths - Strong Products Capabilities

We acquired more than 186 patents and published over 84 research papers. Also, we acquired more than 10 TFDA Health Food certifications on our products.





2017~2020 : 8 countries, 125 awards




Competitive Strengths - State-of-the-Art Production Facilities







Taiwan - Grape King Brand Sales Channels



Our best seller Slim Turmeric Complex

23% of 2020 revenue

挑戰美人力 雙 向 輔 助

*95%高含量薑黃

X 獨家GKC6益生菌

葡萄王生技獨家研發益生菌複方薑黃 成份創新再升級。



Metabolism promotion and digestion/defecation improvement




Energy drinks that restore energy and provides necessary vitamins



Improves digestion and defecation

Our fourth best seller -**Antrodia King** 9% of 2020 revenue

Liver protection and hangover prevention and alleviation





Pro-Partner Overview

4 key numbers of Pro-Partner

 Largest local direct selling company in Taiwan based on revenue.

 One of the fastest growing direct selling companies in Taiwan (15% sales CAGR from 2008 to 2020)

• Second largest overall direct selling company in Taiwan. (2019 market share: 8.3%)

Smallest product range – 35 Health and Beauty products among the top 5

No. 49 in the worldwide direct selling company rankings for 2018

(Source: 2019 DSN Global 100- based on 2018 revenues)






Bai Yi Jie (toothpaste)



- Grape King's Lactobacillus pentosus GK4
 - → Inhibit 13 kinds of oral bacteria & Prevent cavities
- Xylitol
 - → Anti-plaque
- Sodium fluoride
 - → Prevent enamel erosion
- Mint
 - → Sooth teeth

Hi Spray (oral spray)



→ Inhibit 13 kinds of oral bacteria & Prevent cavities

- Sorbitol
 - → Anti-plaque
- Thyme
 - → Freshen breath
- Mint
 - → Sooth teeth






How is Pro-Partner different from other direct selling companies?



Nearly 80% of Pro-Partner's sales are contributed by old members

Pro-Partner sales contribution(2019)



Our member retention rate is remarkably high number among peers

Member retention rate More than 75%

2017

2018 2019

2016

2015

Healthy membership growth

The growth rate of our executive distributors are similar to the growth rate of our members in the past years. This implies that our members are proportionally promoted each year based on their contribution to the group.



How is Pro-Partner different from other direct selling companies?



Products purchase

- ✓ No minimum purchase requirement.
- ✓ No inventory pressure. (Members buy products directly from the company)

Products' uniqueness



- ✓ Higher entry barrier for Products (bioresearched and engineered).
- ✓ Symbol of national certifications.
- ✓ Products are mostly manufactured inhouse rather than outsourced.

Support



✓ Managed by Grape King, a well-respected health food company in Taiwan, so we can offer dedicated customer service and support.

Training



- ✓ All the trainings and venues are held by the company, so we can have consistent training quality.
- ✓ All the trainings are free to members.

Compensation



- ✓ Transparent compensation structure.
- ✓ All purchases can be accumulated.
- ✓ All compensation are paid to sales contribution and directly to the members by the company.










Grape King Shanghai Overview

23

- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.





*In 2019, the overall demand was impacted by China government' s tightening on direct-selling and healthcare industry & in 2020 the China consumption recovery has been softer-than-expected under the pandemic.




Growing our online sales channel



Besides our existing physical retail channels, we are increasing our virtual channel penetration.

Our Virtual channel

- ✓ Grape King online store
- ✓ Online B2C stores
- ✓ TV shopping channels
- ✓ Social Media





Our Capacity and Expansion Plan

Grape King Specialist Fermentation & Manufacturing Site*



Grape King Bio-Tech Headquarter

Grape King Biotech Research Institute



Production	Monthly Capacity					
Line	2019	2020				
Capsules	7 M capsules	7 M capsules				
Fine Granule	2 M pack	2 M pack				
Liquids-Big CC	4.2 M bottles	4.2 M bottles				
Liquids-Small CC	1 M bottles	1 M bottles				
PKL	1.4 M bottles	1.4 M bottles				
PIC/S	0.8 M packs	0.8 M packs				

Production	Capacity				
Line	2019	2020			
Lactobacilli	25 tons	25 tons			
Mushroom	161.5 tons	161.5 tons			
PKL Liquids	80 tons	80 tons			



Monthly Capacity				
2019	2020			
18 M bottles	18 M bottles			
3 M packs	3 M packs			
15 M pack	15 M pack			
7 M capsules	7 M capsules			
63 M capsules	63 M capsules			
	2019 18 M bottles 3 M packs 15 M pack 7 M capsules			



Line	2019	2020	Start
Capsules	13M capsules	13M capsules	-
Fine Granule	15M pack	15M pack	
Powder	1.8M packs	1.8M packs	
Jelly foil	-	7.2M packs**	3Q20



Production	Capacity				
Line	2019	2020			
Lactobacilli	40 tons	40 tons			
Mushroom	60 tons	60 tons			

**Monthly capacity =30,000 packs/hr x 12 hrs/day x 20 working days/month















3129



^{*}Our Specialist Fermentation & Manufacturing Site (Zhongli plant) will relocated to Pinzhen Industrial Zone due to city development plan, expansion for PKL and different forms production line. The new plant construction is schedule to begin in the second half of 2020 with production expected to start in 2023. The relocation won't impact our operating and we expect that once the new facility is fully completed and 100% utilized, it is able to contribute additional NT\$10bn in

^{*} We expect to spend NT\$ 680m capex in 2021 for new plant building and equipment purchases (NT\$ 360m), product line expansion of Biotech Research Institute (NT\$ 180m) and product line expansion for Specialist Fermentation & Manufacturing Site and Bio-Tech Headquarter.





Our Growth Strategies



Key Objectives

Grape King Taiwan

- Market share gain
- Expanding through new adjacencies
- Accelerate overseas ODM & raw materials businesses

Levers

- Market share gain through products upgrade and deeper channels penetration
- Business expansion through penetrating new product categories
- ✓ Continue to promote Grape King's raw material and R&D capabilities in probiotics and medicinal mushrooms.

Pro-Partner


- · Unlock growth ceiling
- · Improving demand forecast, sales visibility, and products time to market
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- Focus on growing younger members.
- Duplicate Taiwan success in new geographies

Grape King Shanghai

- · Clients diversification
- Prepping for the probiotics boom
- Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- Develop non-direct/WeChat customers
- ✓ Capture more business opportunities through local strategic partnerships and alliances

Unleash growth potential through expanding into new adjacencies





Growing on Giant's Shoulder



Channels & Distribution Collaboration

- Physical Channels: Taiwan~6,000 stores/ China~ 400 stores / Southeast Asia ~ 3,000 stores (including convenience stores, pharmacies, department stores)
- Virtual Channels









- **Production Resource Collaboration**
 - Taiwan/overseas mutual OEM production

- New adjacencies (such as F&B) expansion
- R&D collaboration, joint product development
- Products agency
- Food safety enhancement

Our Sustainability Initiatives

2019





4th

Taiwanese participation in RE100

100%

Internal product traceability



+20% YoY

Employee training hours

97% → **99%**

Training participation rate



+43% YoY

Volunteer **Participants**

+17% YoY

Invested in social & community engagement



100%

All employees have free health examinations

Major occupational accidents

TWSE corporate governance score (0-100)

2015

62.14


(Rank: 81%~100%)



2019

96.23

(Rank: 6%~20%)





Financial Performance

Confidential




Financial Highlights


Historical revenue vs. operating profit



Historical EPS vs. ROCE




Historical gross margin vs. operating margin




Note: The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.

Historical cash dividend payout





Revenue Breakdown (2020 v.s. 2019)



1.Grape King Taiwan NT\$ 668 m (+24% YoY)


Thanks to strong sales of our own brand products as well as higher ODM revenues.

2.Pro-Partner NT\$ 7,719 m (-1% YoY)

Though the limitation on physical activities impacted operation in 1H20, the sales improved follow the activities resume in 2H20.

3. Grape King Shanghai NT\$ 781 m (-14% YoY)

China consumption recovery has been softerthan-expected. However our current order visibility prior to the Chinese New Year has remained decent.



Five-Year Income Statement

(NT\$ m)	2015	2017	2017	2010	2019	2020			YoY	(%)		
(MŞ III)	2015	2016	2017	2018	2017	2020	2015	2016	2017	2018	2019	2020
Revenue	7,248	9,185	9,388	9,183	9,239	9,168	15.4	26.7	2.2	(2.2)	0.6	(0.8)
Gross Profit	6,385	7,919	7,865	7,329	7,566	7,537	14.8	24.0	(0.7)	(6.8)	3.2	(0.4)
Operating Expenses	(4,573)	(5,685)	(5,610)	(4,979)	(5,231)	(5,232)	15.4	24.3	(1.3)	(11.2)	5.0	0.0
Operating Profit	1,812	2,234	2,254	2,350	2,335	2,305	13.3	23.3	0.9	4.2	(0.6)	(1.3)
Non Operating Income/(Loss)	70	78	151	77	105	73	(21.5)	11.8	92.6	(49.2)	36.8	(30.2)
Pretax Income	1,883	2,312	2,405	2,427	2,440	2,378	11.4	22.8	4.0	0.9	0.6	(2.5)
Tax Expenses	(336)	(426)	(471)	(537)	(502)	(483)	10.9	26.8	10.6	14.0	(6.5)	(3.7)
Minority interest	(495)	(590)	(583)	(595)	(630)	(623)	11.5	19.2	(1.3)	2.1	5.9	(1.1)
Net Income to Parent	1,052	1,297	1,352	1,295	1,309	1,272	11.6	23.3	4.3	(4.2)	1.1	(2.8)
Basic EPS (NT\$)	8.07	9.82	10.03	9.57	9.63	9.34	11.5	21.7	2.1	(4.6)	0.6	(3.0)
Key Financial Ratios (%)												
Gross Margin	88.1	86.2	83.8	79.8	81.9	82.2						
Operating Expense Ratio	63.1	61.9	59.8	54.2	56.6	57.1						
Operating Margin	25.0	24.3	24.0	25.6	25.3	25.1						
Effect Tax Rate	17.8	18.4	19.6	22.1	20.6	20.3						
Net Margin	14.5	14.1	14.4	14.1	14.2	13.9						

Five-Year Balance Sheet

(NIT\$ m)	2015	2016	2017	2018	2019	2020	YoY (%)					
(NT\$ m)	2015	2010	2017	2010	2017	2020	2015	2016	2017	2018	2019	2020
Total Assets	8,612	9,550	9,892	10,648	11,359	13,104	60.4	10.9	3.6	7.6	6.7	15.4
Cash	1,433	1,899	1,920	2,050	2,146	2,927	4.3	32.6	1.1	6.8	4.7	36.4
AR & NR	97	204	160	171	202	202	(1.9)	111.6	(21.5)	6.8	18.0	(0.2)
Inventories	359	435	492	563	546	689	34.0	21.0	13.1	14.4	(2.9)	26.2
Fixed Assets	5,597	6,084	6,355	5,927	6,454	7,308	170.6	8.7	4.5	(6.7)	8.9	13.2
Total Liabilities	4,393	3,767	3,564	3,715	3,888	5,126	165.9	(14.3)	(5.4)	4.2	4.7	31.8
AP & NP	153	198	323	262	223	255	19.2	29.6	63.2	(18.9)	(15.1)	14.7
Total Borrowing	2,439	1,206	1,022	1,119	1,177	1,921	-	(50.6)	(15.2)	9.5	5.2	63.3
Total Equity	4,220	5,783	6,328	6,933	7,471	7,978	13.5	37.1	9.4	9.6	7.8	6.8
Key Financial Ratios (%)												
A/R Turnover Days	4.8	5.9	7.0	6.5	7.3	7.9						
Inventory Turnover Days	131.0	113.0	109.5	102.4	119.3	136.4						
A/P Turnover Days	58.6	49.9	61.6	56.8	52.2	52.7						
Cash Conversion Days	77.2	69.0	54.9	52.1	74.4	91.6						
ROE (%)	32.1	31.3	27.0	23.7	22.0	19.9						
ROA (%)	15.0	14.3	13.9	12.6	11.9	10.4						
Net debt (cash)/Equity %	23.9	(12.0)	(14.2)	(13.4)	(13.0)	(12.6)						



Dividend Payout and Capex

(NT\$ m)	2015	2016	2017	2018	2019	2020
Net profit	1,052	1,297	1,352	1,295	1,309	1,272
Cash dividend	730	862	903	883	884	948
DPS (NT\$)	5.6	6.4	6.7	6.5	6.5	6.4
Payout ratio	69.4%	65.2%	66.6%	67.9%	67.4%	68.5%
Cash yield	2.6%	3.2%	2.9%	3.0%	3.3%	3.6%
Capex	2,635	736	772	1,116	630	1,214

Notes:

- 1. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.
- 2. The capex for 2020 is mainly used for land acquisition for our Zhongli plant relocation and for new production facilities.
- 3. 2020 cash yield is calculated based on Grape King's 2021/3/2 closing share.





Appendix: Industry Trends

Confidentia



Taiwan health food industry

Taiwan's health food industry is growing

Taiwan health food industry continues to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.

Taiwan health food industry (NT\$ bn) 180 160 140 120 100 80 60 40 20 0 Example 120 100 80 60 A0 20 Source: AC Nielsen

We keep gaining market share in Taiwan

We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both mushroom-based supplements and probiotics.

Grape King's market share in Taiwan health food industry

	<u>2013</u>		2019
Taiwan health food	4.90%	-	5.60%
Mushroom	32.06%	→	44.93%
Probiotics	13.89%	→	30.64%
Energy drink	12.23%	→	11.22%


Source: AC Nielsen, Company data

66

Taiwan direct selling industry

Health food takes up ~60% of direct selling industry in Taiwan

According to Taiwan FTC, health food takes up 60% of the direct selling market share, which shows that direct selling is an important channel for health food products.



Taiwan direct selling industry is strictly regulated with entry barrier



Sales incentive system

- 1) Reasonable product price (mark-up on pricing);
- 2) Reasonable compensation structure (distribution of profit)

Member's system



According to Taiwan's regulation, it is illegal to produce earnings by simply introducing new participants instead of engaging in promotion & selling goods or services. Companies in violation may be subject to imprisonment and/or fines.

Pro-Partner is the only domestic direct selling company in Top 10

Top 10 players have high market concentration



Pro-Partner has highest sales per product among top 3 players

	Rank & Market	Member	Sales contribution				
	shares (%)	s ('000)	Per member (NT\$)	Per product (NT\$m)			
Pro-Partner	2 (9.8%)	200	43,300	288.7			
Nu Skin	3 (5.5%)	120	40,000	21.9			
Amway	1 (13.4%)	350	33,857	41.0			

Source: Company data, FTC. Taiwan Association of Direct Se


China health food industry

China's health food industry grew 21% CAGR between 2011-2018

China's health food industry mainly driven by economic growth, disposable income, and rising health awareness. The industry has been growing for the past 7 years.

China direct selling has significant growth from 2011-2018

Direct selling has become an important distribution channel as sales from direct selling has grown from 26% in 2011 to 47% in 2018.




Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.

China health food industry

Global probiotics market is still growing

According to Statista, global probiotics market has reached US\$40 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.0% CAGR between 2016-2022.



^{*}Notes: Global probiotics market includes probiotics supplement, probiotic yoghurt, and sour milk products.

Grape King is the 7th largest distributor globally

We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.

Rank	Company	Brand	
1	P&G	Align	align
2	SANOFI	Enterogermina	Enterogramen
3	父 大正製業	Shin Biofermin S	SI SI
7	新語王生技 GAAP KING BIO	Probiotics & Prebiotics Super 13 Probiotics & Prebiotic	CS RMA

Source: Euromonitor

China probiotics market

China probiotics market is expected to reach Rmb 85 bn in 2020


China's probiotic consumption remains at a relatively early stage and the supply is mostly dependent on import. According to ASKCI, China probiotics market is forecasted to reach RMB 85 bn dollars by 2020.

Taiwan and China probiotic supplement market are expected

According to Euromonitor, both Taiwan and China's probiotic supplement market are expected to deliver 27% and 23% of growth in 2016-2021, respectively.

China Probiotics Market (2014-2020) (Rmb bn) 100 85 80 60 42 40 20 0 2014 2015 2018(E) 2019(E) 2020(E) 2016 2017 *Notes: China probiotics market includes probiotics supplement, probiotic yoghurt, and sour milk products.

Probiotics Supplements Retail Value (2016-2021)



Source: Euromonitor

